Journal of Vascular Surgery
Volume 51, Issue 1 , Pages 51-56 , January 2010

Cilostazol reduces restenosis after carotid artery stenting

  • Tomoji Takigawa, MD

      Affiliations

    • Department of Endovascular Neurosurgery, Toranomon Hospital, Tokyo, Japan
    • Corresponding Author InformationReprint requests: Tomoji Takigawa, MD, Department of Neurosurgery, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan
    • ,
  • Yuji Matsumaru, MD

      Affiliations

    • Department of Endovascular Neurosurgery, Toranomon Hospital, Tokyo, Japan
    • ,
  • Mikito Hayakawa, MD

      Affiliations

    • Department of Endovascular Neurosurgery, Toranomon Hospital, Tokyo, Japan
    • ,
  • Shigeru Nemoto, MD

      Affiliations

    • Department of Endovascular Surgery, Jichi Medical University, Tochigi, Japan
    • ,
  • Akira Matsumura, MD

      Affiliations

    • Department of Neurosurgery, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan

Received 16 April 2009 ,Accepted 7 August 2009.

References 

  1. Wholey MH, Wholey M, Mathias K, Roubin GS, Diethrich EB, Henry M, et al. Global experience in cervical carotid artery stent placement. Catheter Cardiovasc Interv. 2000;50:160–167
  2. Diethrich EB, Ndiaye M, Reid DB. Stenting in the carotid artery: initial experience in 110 patients. J Endovasc Surg. 1996;3:42–62
  3. Yadav JS, Roubin GS, Iyer S, Vitek J, King P, Jordan WD, et al. Elective stenting of the extracranial carotid arteries. Circulation. 1997;95:376–381
  4. Ouriel K, Yadav J, Green RM. Standards of practice: carotid angioplasty and stenting. J Vasc Surg. 2004;39:916–917
  5. Cremonesi A, Manetti R, Setacci F, Setacci C, Castriota F. Protected carotid stenting: clinical advantages and complications of embolic protection devices in 442 consecutive patients. Stroke. 2003;34:1936–1941
  6. Roubin GS, New G, Iyer SS, Vitek JJ, Al-Mubarak N, Liu MW, et al. Immediate and late clinical outcomes of carotid artery stenting in patients with symptomatic and asymptomatic carotid artery stenosis: a 5-year prospective analysis. Circulation. 2001;103:532–537
  7. Lal BK, Hobson RW, Goldstein J, Geohagan M, Chakhtoura E, Pappas PJ, et al. In-stent recurrent stenosis after carotid artery stenting: life table analysis and clinical relevance. J Vasc Surg. 2003;38:1162–1168discussion 1169
  8. Khan MA, Liu MW, Chio FL, Roubin GS, Iyer SS, Vitek JJ. Predictors of restenosis after successful carotid artery stenting. Am J Cardiol. 2003;92:895–897
  9. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung. 1985;35:1154–1156
  10. Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology. 1988;36:313–320
  11. Ikeda Y, Kikuchi M, Murakami H, Satoh K, Murata M, Watanabe K, et al. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo (Randomized, double-blind cross-over study). Arzneimittelforschung. 1987;37:563–566
  12. Dawson DL, Cutler BS, Meissner MH, Strandness DE. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998;98:678–686
  13. Ishii H, Kumada Y, Toriyama T, Aoyama T, Takahashi H, Yamada S, et al. Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease. Clin J Am Soc Nephrol. 2008;3:1034–1040
  14. Iida O, Nanto S, Uematsu M, Morozumi T, Kotani J, Awata M, et al. Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery. Circ J. 2005;69:1256–1259
  15. Iida O, Nanto S, Uematsu M, Morozumi T, Kitakaze M, Nagata S. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg. 2008;48:144–149
  16. Take S, Matsutani M, Ueda H, Hamaguchi H, Konishi H, Baba Y, et al. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1997;79:1097–1099
  17. Tsuchikane E, Katoh O, Sumitsuji S, Fukuhara A, Funamoto M, Otsuji S, et al. Impact of cilostazol on intimal proliferation after directional coronary atherectomy. Am Heart J. 1998;135:495–502
  18. Sekiya M, Funada J, Watanabe K, Miyagawa M, Akutsu H. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol. 1998;82:144–147
  19. Yamasaki M, Hara K, Ikari Y, Kobayashi N, Kozuma K, Ohmoto Y, et al. Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation. Cathet Cardiovasc Diagn. 1998;44:387–391
  20. Tsuchikane E, Fukuhara A, Kobayashi T, Kirino M, Yamasaki K, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation. 1999;100:21–26
  21. Tanabe Y, Ito E, Nakagawa I, Suzuki K. Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine. Int J Cardiol. 2001;78:285–291
  22. Douglas JS, Holmes DR, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, et al. Cilostazol for Restenosis Trial (CREST) Investigators Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005;112:2826–2832
  23. Veith FJ, Amor M, Ohki T, Beebe HG, Bell PR, Bolia A, et al. Current status of carotid bifurcation angioplasty and stenting based on a consensus of opinion leaders. J Vasc Surg. 2001;33(2 suppl):S111–S116
  24. Wang TJ, Nam BH, Wilson PW, Wolf PA, Levy D, Polak JF, et al. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2002;22:1662–1667
  25. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325:445–453
  26. Chakhtoura EY, Hobson RW, Goldstein J, Simonian GT, Lal BK, Haser PB, et al. In-stent restenosis after carotid angioplasty-stenting: incidence and management. J Vasc Surg. 2001;33:220–225discussion 225-6
  27. Criado FJ, Lingelbach JM, Ledesma DF, Lucas PR. Carotid artery stenting in a vascular surgery practice. J Vasc Surg. 2002;35:430–434
  28. Leger AR, Neale M, Harris JP. Poor durability of carotid angioplasty and stenting for treatment of recurrent artery stenosis after carotid endarterectomy: an institutional experience. J Vasc Surg. 2001;33:1008–1014
  29. Setacci C, de Donato G, Setacci F, Pieraccini M, Cappelli A, Trovato RA, et al. In-stent restenosis after carotid angioplasty and stenting: a challenge for the vascular surgeon. Eur J Vasc Endovasc Surg. 2005;29:601–607
  30. Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, Takai H, et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 1992;20:900–906
  31. Kamishirado H, Inoue T, Mizoguchi K, Uchida T, Nakata T, Sakuma M, et al. Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. Am Heart J. 2002;144:303–308
  32. Hayashi S, Morishita R, Matsushita H, Nakagami H, Taniyama Y, Nakamura T, et al. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension. 2000;35:237–243
  33. Aoki M, Morishita R, Matsushita H, Hayashi S, Nakagami H, Yamamoto K, et al. Inhibition of the p53 tumor suppressor gene results in growth of human aortic vascular smooth muscle cells (Potential role of p53 in regulation of vascular smooth muscle cell growth). Hypertension. 1999;34:192–200
  34. Aoki M, Morishita R, Hayashi S, Jo N, Matsumoto K, Nakamura T, et al. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia. 2001;44:1034–1042
  35. Inoue T, Uchida T, Sakuma M, Imoto Y, Ozeki Y, Ozaki Y, et al. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol. 2004;44:1408–1414
  36. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease. Circulation. 2006;113:e463–e654

 Competition of interest: none.

 The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a competition of interest.

PII: S0741-5214(09)01681-4

doi: 10.1016/j.jvs.2009.08.040

Journal of Vascular Surgery
Volume 51, Issue 1 , Pages 51-56 , January 2010

Article Tools